Review of bone health in women receiving endocrine therapy because of breast cancer

被引：1

作者：

Kollar, Reka ^{[1
]}

Leel-Ossy, Tamas ^{[1
]}

Palffy, Veronika

Dank, Magdolna

Horvath, Csaba

Meszaros, Szilvia

机构：

[1] Semmelweis Egyet, Altalan Orvostud Kar, Belgyogyaszat & Onkol Klinika, Budapest, Hungary

来源：

ORVOSI HETILAP | 2024年 / 165卷 / 21期

关键词：

breast cancer; endocrine therapy; osteoporosis; fracture; MINERAL DENSITY; PREMENOPAUSAL PATIENTS; POSTMENOPAUSAL WOMEN; AROMATASE INHIBITOR; ZOLEDRONIC ACID; FRACTURE RISK; TAMOXIFEN; GOSERELIN; PREVENTS; TRIAL;

D O I：

10.1556/650.2024.33043

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Breast cancer is one of the most common malignancies of women. However, recent advances in early detection screenings and treatment options have reduced mortality, even in the face of growing incidence. Endocrine therapies are commonly used as treatment for patients with hormone-receptor positive breast carcinoma, but are also known to induce bone loss and increase the risk of fractures. Osteoporotic fractures have emerged as an important clinical problem with the improving survival of women with breast cancer. In the present review, we would like to emphasize the importance of the topic by summarizing the published data of the past three decades. Timely diagnostic steps are essential for the detection of reduced bone mineral content and, if necessary, the introduction of treatment for fracture prevention.

引用

页码：813 / 821

页数：9

共 47 条

[1] Bone turnover markers in postmenopausal breast cancer treated with fulvestrant - A pilot study [J].

Agrawal, A. ;

Hannon, R. A. ;

Cheung, K. L. ;

Eastell, R. ;

Robertson, J. F. R. .

BREAST, 2009, 18 (03) :204-207

[2] Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis [J].

Amir, Eitan ;

Seruga, Bostjan ;

Niraula, Saroj ;

Carlsson, Lindsay ;

Ocana, Alberto .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (17) :1299-1309

[3] The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis [J].

Anastasilakis, Athanasios D. ;

Papachatzopoulos, Stergios ;

Makras, Polyzois ;

Gkiomisi, Athina ;

Nikolakopoulos, Panagiotis ;

Polyzos, Stergios A. ;

Ntenti, Charikleia ;

Ballaouri, Iris ;

Gerou, Spyridon ;

Tsachouridou, Olga ;

Papatheodorou, Athanasios ;

Aliazis, Konstantinos ;

Fermanoglou, Sofia ;

Bisbinas, Ilias ;

Yavropoulou, Maria P. .

BONE, 2022, 158

[4] Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen [J].

Ariazi, Eric A. ;

Leitao, Andrei ;

Oprea, Tudor I. ;

Chen, Bin ;

Louis, Teresa ;

Bertucci, Anne Marie ;

Sharma, Catherine G. N. ;

Gill, Shaun D. ;

Kim, Helen R. ;

Shupp, Heather A. ;

Pyle, Jennifer R. ;

Madrack, Alexis ;

Donato, Anne L. ;

Cheng, Dong ;

Paige, James R. ;

Jordan, V. Craig .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (11) :2817-2827

[5] Selective toxic effects of tamoxifen on osteoclasts: Comparison with the effects of oestrogen [J].

Arnett, TR ;

Lindsay, R ;

Kilb, JM ;

Moonga, BS ;

Spowage, M ;

Dempster, DW .

JOURNAL OF ENDOCRINOLOGY, 1996, 149 (03) :503-508

[6] Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials [J].

Bradley, R. ;

Braybrooke, J. ;

Gray, R. ;

Hills, R. K. ;

Liu, Z. ;

Pan, H. ;

Peto, R. ;

Dodwell, D. ;

McGale, P. ;

Taylor, C. ;

Bergh, J. ;

Swain, S. ;

Francis, P. A. ;

Gnant, M. ;

Perrone, F. ;

Regan, M. M. .

LANCET ONCOLOGY, 2022, 23 (03) :382-392

[7] Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis [J].

Chen, Shanshan ;

Bo, Lan ;

Lv, Dan ;

Ma, Fei .

BREAST CARE, 2022, 17 (04) :391-402

[8] Bone health in cancer: ESMO Clinical Practice Guidelines [J].

Coleman, R. ;

Hadji, P. ;

Body, J-J ;

Santini, D. ;

Chow, E. ;

Terpos, E. ;

Oudard, S. ;

Bruland, O. ;

Flamen, P. ;

Kurth, A. ;

Van Poznak, C. ;

Aapro, M. ;

Jordan, K. .

ANNALS OF ONCOLOGY, 2020, 31 (12) :1650-1663

[9] Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials [J].

Dowsett, M. ;

Forbes, J. F. ;

Bradley, R. ;

Ingle, J. ;

Aihara, T. ;

Bliss, J. ;

Boccardo, F. ;

Coates, A. ;

Coombes, R. C. ;

Cuzick, J. ;

Dubsky, P. ;

Gnant, M. ;

Kaufmann, M. ;

Kilburn, L. ;

Perrone, F. ;

Rea, D. ;

Thuerlimann, B. ;

van de Velde, C. ;

Pan, H. ;

Peto, R. ;

Davies, C. ;

Gray, R. ;

Baum, M. ;

Buzdar, A. ;

Sestak, I. ;

Markopoulos, C. ;

Fesl, C. ;

Jakesz, R. ;

Colleoni, M. ;

Gelber, R. ;

Regan, M. ;

von Minckwitz, G. ;

Snowdon, C. ;

Goss, P. ;

Pritchard, K. ;

Anderson, S. ;

Costantino, J. ;

Mamounas, E. ;

Ohashi, Y. ;

Watanabe, T. ;

Bastiaannet, E. .

LANCET, 2015, 386 (10001) :1341-1352

[10] Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230) [J].

Eastell, Richard ;

Hannon, Rosemary A. ;

Cuzick, Jack ;

Dowsett, Mitch ;

Clack, Glen ;

Adams, Judith E. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (08) :1215-1223

← 1 2 3 4 5 →